Cervical cancer incidence higher in states with lower proportion of HPV vaccination rates
the ONA take:
According to new findings presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, researchers from the University of North Carolina Gillings School of Global Public Health in Chapel Hill, North Carolina, the number of adolescent girls receiving the human papillomavirus (HPV) vaccine is much lower in states with higher rates of cervical cancer and cervical cancer-related mortality.
Using the National Immunization Survey-Teen, researchers identified the rates of HPV vaccination in various states, and identified cervical cancer rates in the same states using the United States Cancer Statistics database. States with higher vaccination rates had lower cancer incidence rates and vice versa.
For example, in Massachusetts, 69% of adolescent girls have begun the HPV vaccination series and 6 per 100,000 women develop cervical cancer a year, whereas in Arkansas, 41% of adolescent girls have initiated HPV vaccination and 10 per 100,000 women develop cervical cancer a year. In addition, completion rates of the HPV vaccine course were higher in states where adolescents have higher levels of contact with the healthcare system.
The researchers suggest that more adolescent preventive health care may be needed to improve completion rates of the HPV vaccination series.
Number of adolescent girls receiving the HPV vaccine much lower in states with higher rates of cervical cancer.
The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
HPV vaccines can prevent individuals from developing several types of cancer, including cervical, anal, vaginal, and vulvar cancers. "Cervical cancer incidence and mortality rates vary widely by state," said Jennifer L. Moss, MSPH, a doctoral student in the Department of Health Behavior at the University of North Carolina Gillings School of Global Public Health in Chapel Hill.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|